TV2H vs. BPCR, KLSO, KRM, ADA, WCW, IX, LMS, NBDG, WINV, and TFG
Should you be buying Thames Ventures VCT 2 Healthcare Shs stock or one of its competitors? The main competitors of Thames Ventures VCT 2 Healthcare Shs include BioPharma Credit (BPCR), Kelso Group (KLSO), KRM22 (KRM), Adams (ADA), Walker Crips Group (WCW), i(x) Net Zero (IX), LMS Capital (LMS), NB Distressed Debt Investment Fund (NBDG), Worsley Investors (WINV), and Tetragon Financial (TFG). These companies are all part of the "asset management" industry.
Thames Ventures VCT 2 Healthcare Shs (LON:TV2H) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
38.7% of BioPharma Credit shares are owned by institutional investors. 0.1% of Thames Ventures VCT 2 Healthcare Shs shares are owned by insiders. Comparatively, 7.8% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BioPharma Credit has a net margin of 83.84% compared to Thames Ventures VCT 2 Healthcare Shs' net margin of 0.00%. BioPharma Credit's return on equity of 13.65% beat Thames Ventures VCT 2 Healthcare Shs' return on equity.
BioPharma Credit received 84 more outperform votes than Thames Ventures VCT 2 Healthcare Shs when rated by MarketBeat users.
BioPharma Credit has higher revenue and earnings than Thames Ventures VCT 2 Healthcare Shs. Thames Ventures VCT 2 Healthcare Shs is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioPharma Credit's average media sentiment score of 0.80 beat Thames Ventures VCT 2 Healthcare Shs' score of 0.00 indicating that BioPharma Credit is being referred to more favorably in the news media.
Thames Ventures VCT 2 Healthcare Shs pays an annual dividend of GBX 1 per share and has a dividend yield of 2.1%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 797.3%. Thames Ventures VCT 2 Healthcare Shs pays out -5,000.0% of its earnings in the form of a dividend. BioPharma Credit pays out 5,384.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
BioPharma Credit beats Thames Ventures VCT 2 Healthcare Shs on 11 of the 12 factors compared between the two stocks.
Get Thames Ventures VCT 2 Healthcare Shs News Delivered to You Automatically
Sign up to receive the latest news and ratings for TV2H and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Thames Ventures VCT 2 Healthcare Shs Competitors List
Related Companies and Tools
